Key Highlights

  • NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) announced on September 29, 2026 that it dosed the first participant in SPINOZA, a Phase 2b trial of obicetrapib in about 400 adults with preclinical Alzheimer's disease, and the shares rose 3.6% on September 30.
  • The primary measure is the change in plasma p-tau217, a blood biomarker of Alzheimer's pathology, with secondary biomarkers and the Preclinical Alzheimer's Cognitive Composite 5 score tracked to week 52.
  • Participants receive obicetrapib 10 mg or placebo, are stratified by ApoE genotype, and may enter an optional 26-week extension on active drug.
  • The study builds on signals from a biomarker analysis in the Phase 3 BROADWAY trial, which has not yet been presented publicly or peer reviewed.

What Was Announced

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) develops oral, non-statin medicines for cardiovascular risk. SPINOZA is randomized, double-blind and placebo-controlled, and it enrolls adults with biomarker evidence suggestive of preclinical Alzheimer's who have no noticeable memory or functional symptoms. CEO Michael Davidson called the first dosing an important milestone for expanding the evaluation of obicetrapib in Alzheimer's. The company announced the news at 8:00 a.m. ET on September 29, and the stock moved the next day, so the rise followed a short delay. Sponsors usually report such milestones to show progress, which can lift sentiment even without data.

The Scientific Case

Obicetrapib is an oral CETP inhibitor designed to raise HDL and lower LDL cholesterol, and in the Phase 2 ROSE trial the 10 mg dose cut median LDL cholesterol by 51% on top of high-intensity statins. The Alzheimer's idea is that lipid biology, including the APOE gene that carries cholesterol in the brain, affects disease risk. An earlier Phase 2a study in early Alzheimer's patients who carry ApoE4 suggested improvements in brain cholesterol metabolism. SPINOZA tests this by tracking blood biomarkers such as p-tau217 and Aβ ratios, plus neurodegeneration markers, over 52 weeks. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) retains rights outside Europe, where a partner holds commercialization rights, and it also kept rights to develop obicetrapib for other diseases such as Alzheimer's.

Risks and What to Watch

A biomarker improvement in a 52-week study does not prove slower cognitive decline, and preclinical Alzheimer's trials need long follow-up. Many Alzheimer's programs have failed after encouraging early signals. The trial adds spending before any Revenue from the indication, and the main cardiovascular value of obicetrapib still depends on its Phase 3 and regulatory path. Investors should watch enrollment pace, any interim biomarker disclosures, the BROADWAY biomarker analysis and cash runway. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is valued mainly on its cholesterol franchise, with Alzheimer's as an option.

Where Things Stand

The cholesterol-drug developer is NewAmsterdam Pharma, and its stock rose 3.6% because the start of a 400-patient Alzheimer's trial opens a second, potentially large indication for obicetrapib. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has not reported any efficacy data in Alzheimer's from this trial, and the earlier data came from smaller or analysis-based studies. The balance of evidence is cautiously positive but early, with long timelines. The next catalysts are enrollment progress and the BROADWAY biomarker data.